{"id":12788,"date":"2020-04-25T15:28:08","date_gmt":"2020-04-25T19:28:08","guid":{"rendered":"http:\/\/airpurifierspecialist.com\/store\/?p=12788"},"modified":"2020-05-19T20:53:56","modified_gmt":"2020-05-20T00:53:56","slug":"cytosorbents-ceo-to-discuss-covid-19-pandemic-and-its-cytosorb-treatment-of-cytokine-storm-in-cowen-covid-19-series-conference-call-today","status":"publish","type":"post","link":"https:\/\/airpurifierspecialist.com\/store\/cytosorbents-ceo-to-discuss-covid-19-pandemic-and-its-cytosorb-treatment-of-cytokine-storm-in-cowen-covid-19-series-conference-call-today\/","title":{"rendered":"CytoSorbents CEO to Discuss COVID-19 Pandemic and its CytoSorb\u00ae Treatment of Cytokine Storm in Cowen COVID-19 Series Conference Call Today"},"content":{"rendered":"
\n
\n
\n
\n
\n

MONMOUTH JUNCTION, N.J.<\/span>, April 3, 2020<\/span> \/PRNewswire\/ —\u00a0CytoSorbents Corporation<\/a>\u00a0(NASDAQ: CTSO) a critical care immunotherapy leader commercializing its CytoSorb<\/a>\u00ae blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world,\u00a0announced that its Chief Executive Officer, Dr. Phillip Chan<\/span>, MD, PhD will participate in a conference call, in fireside chat format, with Dr. Joshua Jennings<\/span>, MD, Managing Director and Senior Research Analyst of Equity Research at Cowen and Company, LLC today to discuss the COVID-19 pandemic and the role that CytoSorbents is playing to help treat patients.<\/p>\n

\n

\"CytoSorbents<\/img><\/a><\/p>

CytoSorbents Corporation (NASDAQ: CTSO) is a leader in blood purification to treat cytokine storm and deadly inflammation in life-threatening illnesses with its flagship product, CytoSorb. CytoSorb is approved in the European Union and distributed in 58 countries worldwide. (PRNewsfoto\/CytoSorbents Corporation)<\/figcaption><\/figure>\n

Date and Time:\u00a0 Today, April 3, 2020<\/span> at 1PM EDT<\/span>
<\/br>Registration and weblink:\u00a0
<\/br>https:\/\/www.netroadshow.com\/conferencing\/login?show=30cabb25&confId=15766<\/a><\/p>\n

About CytoSorbents Corporation (NASDAQ: <\/b>CTSO<\/b><\/a>)<\/b><\/p>\n

CytoSorbents Corporation<\/a>\u00a0is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb\u00ae<\/a>\u00a0is approved in the European Union with distribution in 58 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb\u00ae has been used in more than 80,000 human treatments to date.<\/p>\n

CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of nearly $29<\/span> million\u00a0from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM),\u00a0the U.S. Army, U.S. Special Operations Command (USSOCOM), the U.S. Air Force, Air Force Material Command (USAF\/AFMC) and others. The Company has numerous products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and multiple applications pending, including CytoSorb-XL\u2122, HemoDefend\u2122, VetResQ\u2122, K+<\/sup>ontrol\u2122, ContrastSorb, DrugSorb, and others.\u00a0 For more information, please visit the Company’s websites at www.cytosorbents.com<\/a> and www.cytosorb.com<\/a> or follow us on Facebook<\/a>\u00a0and Twitter<\/a>.<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on\u00a0March 5, 2020, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements, particularly in light of the current coronavirus pandemic, where businesses can be impacted by rapidly changing state and federal regulations, as well as the health and availability of their workforce. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.\u00a0<\/p>\n

Please Click to Follow Us on <\/b>Facebook<\/b><\/a>\u00a0and <\/b>Twitter<\/b><\/a><\/p>\n

CytoSorbents Contact:<\/b>\u00a0
<\/br>Amy Vogel<\/span>
<\/br>Investor Relations
<\/br>(732) 398-5394
<\/br>avogel@cytosorbents.com<\/a><\/p>\n

Investor Relations Contact:<\/b>\u00a0
<\/br>Jeremy Feffer<\/span>
<\/br>LifeSci Advisors
<\/br>917-749-1494
<\/br>jeremy@lifesciadvisors.com<\/a><\/p>\n

Public Relations Contact:
<\/br><\/b>Eric Kim\u00a0
<\/br>Rubenstein Public Relations
<\/br>212-805-3052
<\/br>ekim@rubensteinpr.com<\/a>\u00a0\u00a0<\/p>\n

\n

\"Cision\"<\/img><\/p>

Cision<\/figcaption><\/figure>\n

View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/cytosorbents-ceo-to-discuss-covid-19-pandemic-and-its-cytosorb-treatment-of-cytokine-storm-in-cowen-covid-19-series-conference-call-today-301035041.html<\/a><\/p>\n

SOURCE CytoSorbents Corporation<\/p>\n<\/div>\n<\/article>\n<\/div>\n<\/div>\n<\/article>\n

Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

MONMOUTH JUNCTION, N.J., April 3, 2020 \/PRNewswire\/ —\u00a0CytoSorbents Corporation\u00a0(NASDAQ: CTSO) a critical care immunotherapy leader commercializing its CytoSorb\u00ae blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world,\u00a0announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD will participate in a conference call, in fireside…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[],"_links":{"self":[{"href":"https:\/\/airpurifierspecialist.com\/store\/wp-json\/wp\/v2\/posts\/12788"}],"collection":[{"href":"https:\/\/airpurifierspecialist.com\/store\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/airpurifierspecialist.com\/store\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/airpurifierspecialist.com\/store\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/airpurifierspecialist.com\/store\/wp-json\/wp\/v2\/comments?post=12788"}],"version-history":[{"count":1,"href":"https:\/\/airpurifierspecialist.com\/store\/wp-json\/wp\/v2\/posts\/12788\/revisions"}],"predecessor-version":[{"id":16130,"href":"https:\/\/airpurifierspecialist.com\/store\/wp-json\/wp\/v2\/posts\/12788\/revisions\/16130"}],"wp:attachment":[{"href":"https:\/\/airpurifierspecialist.com\/store\/wp-json\/wp\/v2\/media?parent=12788"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/airpurifierspecialist.com\/store\/wp-json\/wp\/v2\/categories?post=12788"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/airpurifierspecialist.com\/store\/wp-json\/wp\/v2\/tags?post=12788"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}